Contineum Dials Back Plans with $110M IPO to Fund Neuroinflammatory Trials

Contineum Therapeutics went public on Friday, trading on the Nasdaq Global Select Market under the ticker symbol CTNM and dialing back its expectations to raise $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.